Demant

Q1 met expectations, but the guidance downgrade was a surprise

08/05/25 -"Demant’s Q1 results met market expectations. Growth in Hearing Care was counterbalanced by weakness in Hearing Aids. Meanwhile, Diagnostics remained stable. However, profitability fell short of ..."

PDF page sample
Pages
58
Language
English
Published on
08/05/25
Download
You may also be interested by these reports :
27/02/26
bioMerieux’s Q4 sales met expectations, with top-line growth driven by both segments. Management fulfilled its 2025 commitments and provided 2026 ...
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...
25/02/26
Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported ...
24/02/26
FMC delivered a strong Q4 profit beat, with record profitability driven by accelerated FME25+ savings and operational discipline. FY 25 results also ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO